General Announcement::FIRST SUBLINGUAL KETAMINE DRUG FOR TREATMENT OF ACUTE PAIN TO BE EVALUATED IN EOP2 MEETING WITH FDA

Issuer & Securities

Issuer/ Manager
IX BIOPHARMA LTD.
Securities
IX BIOPHARMA LTD. - SG1BD9000009 - 42C
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
21-May-2019 17:31:41
Status
New
Announcement Sub Title
FIRST SUBLINGUAL KETAMINE DRUG FOR TREATMENT OF ACUTE PAIN TO BE EVALUATED IN EOP2 MEETING WITH FDA
Announcement Reference
SG190521OTHRG3NR
Submitted By (Co./ Ind. Name)
Lee Wei Hsiung
Designation
Company Secretary
Description (Please provide a detailed description of the event in the box below)
Please refer to the attachment.

Attachments

Press Release_Wafermine EOP2 Meeting.pdf
Total size =132K